Tandem Diabetes Care

Name

Tandem Diabetes Care

Legal name

Tandem Diabetes Care, Inc.

Website

https://tandemdiabetes.com

Company type

Public

Founded year

2011

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Automated Insulin Delivery Systems

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF)

akta.pro secondary industries

Insulin Pumps (Tubed) (HLAHAHAB), Pen Injectors (Insulin/GLP-1/Other Pens) (HLAHAIAC), Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ), Insulin Pen Needles, Syringes & Infusion Sets (Consumables) (HLAHAHAE), Patch Pumps & Wearable Insulin Delivery (HLAHAHAC)

Keywords

• Automated insulin delivery
• Insulin pump systems
• Diabetes management devices
• Hybrid closed-loop systems
• Insulin pump consumables

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Insulin Pump Hardware Sales: Sale of insulin pump devices (t:slim X2, Tandem Mobi) to patients via prescription through pharmacy and DME channels. Revenue recognized at point of shipment or over time depending on channel. Traditional DME channel involved upfront durable medical equipment reimbursement. Transitioning to pharmacy-based PayGo model with lower upfront revenue but higher recurring supply revenue over patient lifetime.
2. Insulin Pump Supplies (Recurring): Recurring revenue from consumables including insulin cartridges (3mL for t:slim X2, 2mL for Tandem Mobi), infusion sets (AutoSoft 90, AutoSoft 30, AutoSoft XC, VariSoft, TruSteel), and adhesive sleeves. Under PayGo pharmacy model, generates approximately $350 per month per patient from supplies, compared to ~$83 per month through traditional DME channels. Projected to double reimbursement over 4-year product lifespan.
3. International Direct Sales: Direct commercial operations launched in Q1 2026 in the UK, Switzerland, and Austria, transitioning from distributor model. International expansion expected to boost average selling prices by at least 30% compared to distributor model. International markets include multiple European countries where t:slim X2 is already available. Tandem Mobi system expected to launch in select European countries in H2 2026.
4. Software and Connectivity Services: Revenue from Tandem Source platform and mobile applications (Tandem t:slim mobile app, Tandem Mobi mobile app). Platform enables pump data management, healthcare provider sharing, and remote monitoring. The Tandem Device Updater enables remote software updates for pumps.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels7 records

Core offering

Tandem Diabetes Care designs, manufactures, and sells automated insulin delivery (AID) systems for people with insulin-dependent type 1 and type 2 diabetes. Its two pump platforms — the t:slim X2 insulin pump and the Tandem Mobi system — are powered by the proprietary Control-IQ+ predictive algorithm that integrates with continuous glucose monitors to automatically adjust insulin delivery. The company also generates recurring revenue from consumables (insulin cartridges and infusion sets), offers the Tandem Source cloud platform for data management, and supports companion mobile applications on iOS and Android.

Product overview

Tandem Diabetes Care offers a portfolio of insulin delivery and diabetes management products centered on two automated insulin delivery (AID) pump platforms — the Tandem Mobi System (tubular, smartphone-controlled) and the t:slim X2 Insulin Pump (color touchscreen). Both pumps are powered by Control-IQ+ technology, a predictive algorithm that automatically adjusts insulin based on CGM data. The portfolio includes infusion sets (AutoSoft 90, AutoSoft 30, AutoSoft XC, VariSoft, TruSteel), Tandem Source cloud platform, companion mobile apps, and remote software update capability. Tandem has expanded into tubeless pump technology through acquisition of AMF Medical and its Sigi patch pump. The company targets type 1 and type 2 diabetes patients with its AID systems, recently gaining FDA and CE Mark clearance for pregnancy indications.

Differentiator

Problem solved

Functional benefit

Products and services

• Tandem Mobi System The Tandem Mobi is the company's smallest and lightest automated insulin delivery system, designed to be worn on-body and controllable via a compatible smartphone app (iOS and Android). It is powered by Control-IQ+ technology, uses 2mL insulin cartridges, includes an on-device bolus button as backup to smartphone control, and is available to pump users in the United States. Indicated for people with type 1 diabetes (ages 2 and above) and adults with type 2 diabetes.
• t:slim X2 Insulin Pump The t:slim X2 is a compact insulin pump with a slim color touchscreen, multiple continuous glucose monitor compatibility options (Dexcom G6, G7, G7 15 Day, and Abbott FreeStyle Libre 3 Plus), and Control-IQ+ automated insulin delivery technology. It uses 3mL insulin cartridges and supports remote software updates via the Tandem Device Updater. Cleared for people with type 1 diabetes (ages 2+) and adults with type 2 diabetes.
• Tandem Source Platform Tandem Source is a cloud-based diabetes management software platform that enables users to review insulin pump data, share therapy data with healthcare providers, and manage pump settings remotely. It serves as the central data backbone connecting the t:slim X2 and Tandem Mobi pumps, the t:connect HCP application used by providers, and the companion mobile apps.
• Tandem Infusion Sets Tandem-branded insulin pump infusion sets sold as recurring supplies for use with the t:slim X2 and Tandem Mobi pumps. The product line includes AutoSoft 90 (90-degree insertion), AutoSoft 30 (30-degree insertion), VariSoft (variable angle insertion), and TruSteel (steel cannula) options, all using the t:lock connector. Under the PayGo pharmacy model, infusion sets and cartridges generate approximately $350 per patient per month in recurring revenue.

Quantifiable outcome

• Users spent 12.6% more time (approximately 3 additional hours per day) in pregnancy-specific glucose target range (63-140 mg/dL) compared to standard therapy, based on CIRCUIT trial published in JAMA.
• +4 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability2 records

Feature8 records

Partnerships

Eight partnerships are on record, tiered minor and core.

• University of Virginia School of Data ScienceminorStrategic or Co-development Partner · 27 January 2026UVA researcher Heman Shakeri leads a $4.7 million project to develop next-generation fully closed-loop insulin delivery systems combining adaptive machine learning algorithms with ultra-rapid-acting insulin. Collaboration between UVA, University of Colorado Anschutz Medical Campus, and UCSF, with Tandem Diabetes Care and Arecor providing in-kind contributions totaling $800,000 alongside $3.9 million from Breakthrough T1D and the Helmsley Charitable Trust. Clinical trials will be conducted at all three institutions.
• University of Colorado Anschutz Medical CampusminorStrategic or Co-development Partner · 27 January 2026Partner in $4.7M research project for fully closed-loop insulin delivery systems. University of Colorado Anschutz Medical Campus is one of three participating clinical trial sites alongside UVA and UCSF.
• UCSFminorStrategic or Co-development Partner · 27 January 2026Partner in $4.7M research project for fully closed-loop insulin delivery systems. UCSF is one of three participating clinical trial sites alongside UVA and University of Colorado.
• ArecorminorStrategic or Co-development Partner · 27 January 2026Arecor provides in-kind contributions of $800,000 (part of $4.7M total project) to a research collaboration developing fully closed-loop insulin delivery systems. Arecor specializes in formulation of biopharmaceuticals including ultra-rapid-acting insulin.
• AMF Medical SAcoreStrategic or Co-development Partner · 23 January 2023Tandem acquired Swiss developer AMF Medical SA, which produces the Sigi insulin patch pump. The acquisition completed January 23, 2023. Deal valued at up to CHF 192 million (~$206.5 million), including CHF 8 million previously paid, CHF 62.4 million at closing, and up to CHF 129.6 million in contingent milestone payments. The Sigi pump is ergonomic, rechargeable, and compatible with automated insulin delivery technology, currently under development.
• Capillary BiomedicalcoreStrategic or Co-development Partner · 21 July 2022Tandem acquired infusion set developer Capillary Biomedical on July 21, 2022. The acquisition aims to expand Tandem's portfolio with new infusion set solutions that extend wear time, reduce occlusions, and reduce body burden and waste. Financial terms were not disclosed. The technology is currently in development and not commercially available.
• Abbott LaboratoriescoreTechnology or IntegrationTandem's t:slim X2 insulin pump is now compatible with Abbott's FreeStyle Libre 3 Plus CGM sensor in the United States, marking the start of a global rollout. The integration enables Tandem AID systems to work with Abbott's CGM technology alongside existing Dexcom integration. Abbott and Tandem are part of a broader ecosystem of integration partners including Bigfoot Biomedical, Insulet, Novo Nordisk, Sanofi, and Ypsomed/CamDiab.
• DexcomcoreTechnology or IntegrationTandem AID systems (t:slim X2 and Tandem Mobi) integrate with Dexcom G6 and G7 continuous glucose monitoring systems. The t:slim X2 is compatible with the Dexcom G7 15 Day CGM System. Dexcom G6 integration enables Control-IQ+ automated insulin delivery. Tandem AID systems are among Dexcom's integrated insulin delivery partners.

Scale indicators16 records

Recent moves8 records

Expansion highlights6 records

Emerging players

• Bigfoot Biomedical: Bigfoot Biomedical is developing the Bigfoot Unity smart pen system and connected insulin delivery offerings, with integrations across Abbott's FreeStyle Libre ecosystem. It overlaps with Tandem in insulin-requiring diabetes management, particularly in type 2 diabetes where Tandem's new CE Mark indication is targeted.
• EOFlow: EOFLOW manufactures the EOPatch tubeless patch insulin pump, a direct competitor in the wearable/patch pump category where Tandem is building with the Sigi and tubeless Mobi pipeline. Notable overlap in form factor and target patient segment, though with limited U.S. commercial scale.
• Beta Bionics: Beta Bionics' iLet bionic pancreas is an emerging AID system for type 1 diabetes that integrates with Dexcom CGM. It is a niche but technically credible AID competitor targeting similar patient populations and prescriber channels as Tandem.

Direct peers

• Insulet Corporation: Insulet's Omnipod 5 is the leading tubeless patch insulin pump with AID capability and the most direct competitor to Tandem's t:slim X2 and Tandem Mobi across both type 1 and type 2 diabetes. Both companies compete for payer formulary access, HCP prescribing, and recurring supply revenue, and Insulet is the benchmark competitor Tandem's Sigi patch and tubeless Mobi pipeline aim to challenge.
• Ypsomed: Ypsomed partners with CamDiab to offer an AID system (YpsoPump + CamAPS FX) integrated with Abbott's FreeStyle Libre, making it a direct competitor to Tandem in European markets and globally. Both compete for type 1 diabetes AID adoption and share the Abbott CGM integration relationship.

Broad incumbents

• Medtronic: Medtronic's MiniMed 780G is an established automated insulin delivery system integrated with its own Guardian CGM, and the company is the global incumbent in diabetes hardware. Competes with Tandem in the AID category with broader scale, an integrated CGM offering, and significant international distribution.
• Roche Diabetes Care: Roche's Accu-Chek insulin pumps and broader diabetes portfolio position it as an established incumbent in diabetes management devices. While its pump offering has a smaller share in AID specifically, Roche competes in the same endocrinology and patient channels as Tandem, particularly in Europe.
• Abbott Diabetes Care: Abbott's FreeStyle Libre 3 Plus is now integrated with Tandem's t:slim X2 and represents a key second-source CGM partner alongside Dexcom. Abbott operates the largest CGM installed base globally and is an ecosystem incumbent whose roadmap, pricing, and partner strategy directly affect Tandem's competitive positioning.
• Dexcom: Dexcom's G6 and G7 CGM systems are core to Tandem's Control-IQ+ AID offering and a key interoperability partner. As CGM becomes increasingly central to diabetes management, Dexcom represents both a critical partner and an ecosystem incumbent with potential to expand into adjacent automated delivery offerings.

Others

• Arecor: Arecor is a specialty biopharmaceutical company developing ultra-rapid-acting insulin formulations and is a research partner with Tandem, UVA, University of Colorado, and UCSF on a $4.7M fully closed-loop AID project. Included as an ecosystem/technology partner rather than a direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/tandemdiabetes
• Facebookfacebook.com/TandemDiabetes
• LinkedInlinkedin.com/company/tandem-diabetes-care

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries3 records

Funding overview

Funding rounds9 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tandem Diabetes Care